Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA

YANG Tingfang; WANG Li; ZHANG Yong

doi:10.3971/j.issn.1000-8578.2021.21.0221

Cancer Research on Prevention and Treatment > 2021 > 48(8): 774-781. > DOI: 10.3971/j.issn.1000-8578.2021.21.0221

YANG Tingfang, WANG Li, ZHANG Yong. Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 774-781. DOI: 10.3971/j.issn.1000-8578.2021.21.0221

Citation:

PDF (9040 KB)

Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA

YANG Tingfang^{1, 2},
WANG Li³,
ZHANG Yong^2, ,

1.
Graduate School of Kunming Medical University, Kunming 650500, China
2.
Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
3.
Department of Pathology, The First People's Hospital of Yunnan Province, Kunming 650032, China

Funding:

National Natural Science Foundation of China 81860557

More Information

Corresponding author:
ZHANG Yong, E-mail: newkaryon@163.com
Received Date: February 25, 2021
Revised Date: June 17, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the expression and prognostic value of FOXO1 gene in liver cancer tissues based on TCGA and HPA databases.
Methods
The RNA-seq data of FOXO1 gene in liver cancer were downloaded from TCGA. The difference of FOXO1 gene expression between tumor and adjacent tissues was obtained via R software. The correlation between FOXO1 and clinicopathological features of liver cancer patients was analyzed. Survival analysis was carried out to evaluate the prognostic significance of FOXO1 gene expression in liver cancer patients. Univariate and multivariate Cox analyses were performed to explore prognostic factors. The correlation between FOXO1 expression and TIICs in tumor microenvironment was performed by CIBERSORT. KEGG pathways enrichment analysis was performed for the potential function of FOXO1 gene in liver cancer.
Results
FOXO1 was downregulated in liver cancer tissues compared with normal tissues (P=1.321E-15). Survival analysis showed that high expression of FOXO1 was positively associated with favorable OS of liver cancer patients (P < 0.05). Clinical stage, T and M stages could be prognostic indicators while FOXO1 wasn't an independent prognostic factor in patients with liver cancer. In TME of liver cancer, the expression of FOXO1 was positively correlated with resting memory CD4 T cells and naive B cells while negatively related to activated memory CD4 T cells and macrophages M2. GSEA identified that FOXO1 participated in multiple cancer-related pathways.
Conclusion
FOXO1 is down-regulated in liver cancer tissues, and its expression level is associated with OS of patients. FOXO1 might be a biomarker related to the prognosis of liver cancer patients and is expected to be a target for diagnosis and treatment of liver cancer.
- FOXO1,
- Liver cancer,
- TCGA

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (28)

References

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
[3]	Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival[J]. J Hepatol, 2019, 70(6): 1262-1277. doi: 10.1016/j.jhep.2019.01.028
[4]	Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies[J]. Mol Cancer, 2017, 16(1): 149. doi: 10.1186/s12943-017-0712-x
[5]	Sia D, Villanueva A, Friedman SL, et al. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis[J]. Gastroenterology, 2017, 152(4): 745-761. doi: 10.1053/j.gastro.2016.11.048
[6]	Qiu Z, Li H, Zhang Z, et al. A Pharmacogenomic Landscape in Human Liver Cancers[J]. Cancer Cell, 2019, 36(2): 179-193. doi: 10.1016/j.ccell.2019.07.001
[7]	Kim CG, Lee H, Gupta N, et al. Role of Forkhead Box Class O proteins in cancer progression and metastasis[J]. Semin Cancer Biol, 2018, 50: 142-151. doi: 10.1016/j.semcancer.2017.07.007
[8]	Shi F, Li T, Liu Z, et al. FOXO1: Another avenue for treating digestive malignancy?[J]. Semin Cancer Biol, 2018, 50: 124-131. doi: 10.1016/j.semcancer.2017.09.009
[9]	Gryder BE, Yohe ME, Chou HC, et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability[J]. Cancer Discov, 2017, 7(8): 884-899. doi: 10.1158/2159-8290.CD-16-1297
[10]	Yu JM, Sun W, Wang ZH, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription[J]. Nat Commun, 2019, 10(1): 5720. doi: 10.1038/s41467-019-13700-6
[11]	Han GH, Chay DB, Nam S, et al. Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer[J]. BMC Cancer, 2019, 19(1): 1202. doi: 10.1186/s12885-019-6406-6
[12]	Chae YC, Kim JY, Park JW, et al. FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer[J]. Nucleic Acids Res, 2019, 47(4): 1692-1705. doi: 10.1093/nar/gky1230
[13]	Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion[J]. Cancer Res, 2011, 71(9): 3257-3267. doi: 10.1158/0008-5472.CAN-10-2603
[14]	汤庆. 原发性肝癌发病年轻化的原因分析[J]. 世界最新医学信息文摘, 2015, 15(53): 95. doi: 10.3969/j.issn.1671-3141.2015.53.079 Tang Q. Analysis of the causes of the younger trend incidence of primary liver cancer[J]. Shijie Zui Xin Yi Xue Xin Xi Wen Zhai, 2015, 15(53): 95. doi: 10.3969/j.issn.1671-3141.2015.53.079
[15]	Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10): 599-616. doi: 10.1038/s41571-018-0073-4
[16]	Alharbi MA, Zhang C, Lu C, et al. FOXO1 Deletion Reverses the Effect of Diabetic-Induced Impaired Fracture Healing[J]. Diabetes, 2018, 67(12): 2682-2694. doi: 10.2337/db18-0340
[17]	Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction[J]. Nature, 2003, 423(6939): 550-555. doi: 10.1038/nature01667
[18]	Chi HC, Chen SL, Cheng YH, et al. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FOXO1 and Bim pathway[J]. Cell Death Dis, 2016, 7(8): e2324. doi: 10.1038/cddis.2016.227
[19]	Calvisi DF, Ladu S, Pinna F, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis[J]. Gastroenterology, 2009, 137(5): 1816-1826. doi: 10.1053/j.gastro.2009.08.005
[20]	Jiang TY, Pan YF, Wan ZH, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma[J]. Sci Transl Med, 2020, 12(562): eaay0152. doi: 10.1126/scitranslmed.aay0152
[21]	Frampton G, Ueno Y, Quinn M, et al. The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(11): G1202-G1211. doi: 10.1152/ajpgi.00104.2012
[22]	Wang Y, Lyu Z, Qin Y, et al. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma[J]. Theranostics, 2020, 10(25): 11535-11548. doi: 10.7150/thno.45261
[23]	Zheng CH, Zheng, LT, Yoo JK, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing[J]. Cell, 2017, 169(7): 1342-1356. e16. doi: 10.1016/j.cell.2017.05.035
[24]	Zhang Z, Ma L, Goswami S, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma[J]. Oncoimmunology, 2019, 8(4): e1571388. doi: 10.1080/2162402X.2019.1571388
[25]	Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma[J]. J Clin Oncol, 2012, 30(21): 2678-2683. doi: 10.1200/JCO.2011.37.8539
[26]	Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 6220. doi: 10.1038/s41598-018-24437-5
[27]	Trinité B, Chan CN, Lee CS, et al. Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells[J]. PLoS One, 2014, 9(10): e110719. doi: 10.1371/journal.pone.0110719
[28]	Cafri G, Yossef R, Pasetto A, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients[J]. Nat Commun, 2019, 10(1): 449. doi: 10.1038/s41467-019-08304-z

Cited By

Cited by

Periodical cited type(5)

1.	周子怡, 黄芝瑛. 放射性核素偶联药物的非临床安全性评价关注要点. 药物评价研究. 2025(07)
2.	邹驰，吴非，林琅，易娟，饶文洁. 免疫检查点抑制剂致重症肌无力危象前状态合并心肌炎、肌炎、肝功能不全1例. 临床神经病学杂志. 2025(03): 232-233 .
3.	张欣，侯晓露，侯俊玲，梅婷. NO与PD-1抗体协同效应在抗肿瘤治疗中的作用及其机制研究进展. 生物化工. 2024(05): 239-242+246 .
4.	路支超，孟艳丽，张霞，邹静雯，张歆，许莉莉. 基于真实世界监测数据分析山东省PD-1抑制剂不良反应发生特点. 中国医院药学杂志. 2024(23): 2779-2783 .
5.	徐洁欢，邓玉屏，李耀军，廉萍，叶枫. miR-381-3p调控PD-L1对卵巢癌细胞卡铂化疗耐药的影响. 中国医药导刊. 2024(09): 929-936 .

Other cited types(4)

Figures(5) / Tables(1)

Get Citation

PDF

XML

Article views (3238) PDF downloads (866) Cited by(9)

Turn off MathJax

Article Contents

Abstract

References

Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA